RARECast

A podcast by RARECast - Thursdays

Thursdays

Categories:

516 Episodes

  1. Designing Clinical Trials with the Patient in Mind

    Published: 7/28/2022
  2. Keeping Clinical Trials Running Smoothly

    Published: 7/21/2022
  3. A Vision for Patient-Centric Gene Therapy Development

    Published: 7/14/2022
  4. Using Genetic Testing to Address Disparities in Care for Kidney Disease

    Published: 7/7/2022
  5. Why Reforms to the Accelerated Approval Pathway Threaten Rare Disease Drug Development

    Published: 6/30/2022
  6. A Longstanding Academic-Nonprofit Collaboration Gives Rise to an ALS Drug Company

    Published: 6/16/2022
  7. Targeting Regulatory RNA to Upregulate Gene Expression to Treat Rare Diseases

    Published: 6/9/2022
  8. Developing a New Approach to Treat Rare, Autoimmune Conditions

    Published: 6/2/2022
  9. Bridging the Gap Between Basic and Commercial Research for Rare Disease

    Published: 5/26/2022
  10. Stoking Functional Copies of Genes to Compensate for Mutated Ones

    Published: 5/19/2022
  11. Targeting ALS with Synergistic Combinations of Therapies

    Published: 5/13/2022
  12. How a Polish Rare Disease Organizations Is Helping Its Ukrainian Neighbors

    Published: 5/5/2022
  13. Powering a New Era of Genetic Medicine

    Published: 4/28/2022
  14. Searching for a Diagnosis

    Published: 4/21/2022
  15. A Novel Way to Deliver Rare Disease Therapies

    Published: 4/14/2022
  16. Bringing Diversity, Equity, and Inclusion to the Books We Read

    Published: 4/7/2022
  17. From Mila to Millions: Scaling N of 1 Therapies

    Published: 3/31/2022
  18. Genetically Modifying Patients’ Skin Cells to Treat Rare Diseases

    Published: 3/24/2022
  19. Targeting Rare, Immunologic Disorders

    Published: 3/18/2022
  20. Harnessing a Natural Mechanism to Silence Disease

    Published: 3/10/2022

7 / 26

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.